Home / About
About Kestrel
Collaborative science against frontotemporal dementia
Kestrel Neuroscience is a nonprofit research foundation. We bring world-class investigators together on the causes of FTD and related neurodegenerative diseases, and move the most promising discoveries toward treatment.
Purpose
Vision and mission
Our vision
A world where people maintain healthy, resilient brains throughout their lifetime because neurodegenerative disease can be prevented and cured.
Our mission
To discover the causes of FTD and related neurodegenerative diseases and accelerate treatments, prevention, and cures through collaborative science.
Strategy
How we pursue it
We support collaborative, discovery-driven science at the earliest stages of the drug development pipeline.
- 01Identify the genetic and molecular causes of FTD and closely related disorders such as amyotrophic lateral sclerosis (ALS).
- 02Explain the cellular and biological mechanisms that drive neurodegeneration.
- 03Discover, validate and prioritize new therapeutic targets for translation.
Kestrel advances the most promising discoveries toward preclinical development, so that industry and clinical partners can carry them into trials and, ultimately, to patients.
Organization
Who we are
Kestrel Neuroscience Inc. (formerly FTD Frontiers Neuroscience Inc.) is a nonprofit 501(c)(3) public charity, incorporated in Delaware in 2025 and governed by an independent board of directors.
Kestrel shares founders with the Bluefield Project to Cure FTD, an independent organization that supports research to advance FTD therapeutics and reduce barriers to clinical success.
| Legal name | Kestrel Neuroscience Inc. |
|---|---|
| Status | 501(c)(3) public charity |
| EIN | 39-2228320 |
| Incorporated | Delaware, 2025 |
| Mailing address | PO Box 2545, Carrollton, GA 30112 |
| info@kestrelneuroscience.org |